Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T17:22:22.714Z.
Calculation as of: 2026-10-06T17:22:22.714Z.
Quote observation: 2026-10-06T17:20:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fa669979e2b3f995ef920df13c3a539cab2f3704a4556e475e3dd75e53b0e3a2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Kestra Medical Technologies, Ltd.
Market Cap
$1.60B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.62B
EBITDA Yield
14.89%
TTM Avg
10.69%
3Y Avg
8.08%
5Y Avg
6.99%
Market Cap
$1.64B
EBITDA Yield
1.75%
TTM Avg
1.16%
3Y Avg
1.16%
5Y Avg
1.16%
Market Cap
$1.54B
EBITDA Yield
N/A
TTM Avg
1.78%
3Y Avg
1.78%
5Y Avg
1.78%
Market Cap
$1.53B
EBITDA Yield
23.05%
TTM Avg
27.65%
3Y Avg
18.18%
5Y Avg
14.75%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kestra Medical Technologies, Ltd. (KMTS) | $1.60B | N/A | N/A | N/A | N/A |
| Omnicell, Inc. (OMCL)vs › | $1.59B | 9.42% | 6.49% | 5.12% | 4.30% |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.61B | N/A | N/A | N/A | N/A |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.62B | 14.89% | 10.69% | 8.08% | 6.99% |
| Septerna Inc (SEPN)vs › | $1.63B | N/A | N/A | N/A | N/A |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.64B | 1.75% | 1.16% | 1.16% | 1.16% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 20.29% | 5.47% | 8.19% | 12.57% |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | N/A | 1.78% | 1.78% | 1.78% |
| Nutex Health, Inc. (NUTX)vs › | $1.53B | 23.05% | 27.65% | 18.18% | 14.75% |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.53B | N/A | 4.60% | 4.60% | 4.60% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
